(Q41504802)

1 October 2017

1 reference

title

Fetal erythropoiesis and the diagnosis and treatment of hemoglobin disorders in the fetus and child (English)

1 reference

1 October 2017

1

Olivieri NF

1 reference

PubMed ID

9190035

1 October 2017

language of work or name

1 reference

1 February 1997

1 reference

1 October 2017

Seminars in Perinatology

1 reference

1 October 2017

21

1 reference

1 October 2017

1

1 reference

1 October 2017

63-69

1 reference

The haemoglobin constitution of infants with the haemoglobin Bart's hydrops foetalis syndrome

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Survival of a hydropic infant with homozygous α-thalassemia-1

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Normal long-term survival with alpha-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Long-term survival of a baby with homozygous alpha-thalassemia-1

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Intrauterine therapy for homozygous alpha-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Marrow transplantation in patients with thalassemia responsive to iron chelation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Public involvement in medical ethics

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Levels of fetal hemoglobin necessary for treatment of sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Benign sickle-cell anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Hb F Synthesis in Sickle Cell Anaemia: a Comparison of Saudi Arab Cases with those of African Origin

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Genotype-phenotype correlations in beta-thalassemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Pain in sickle cell disease. Rates and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Developmental genetics of the human haemoglobins

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Hydroxyurea therapy in children severely affected with sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Functional asplenia in sickle-cell anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+Thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

Developmental and acquired variations in erythrocyte carbonic anhydrase isozymes.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-0005%2897%2980021-3

7 January 2021

10.1016/S0146-0005(97)80021-3

Identifiers

DOI

1 reference

release_mwlpwhzzkzhdhnjme4qwj7ya44

1 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mwlpwhzzkzhdhnjme4qwj7ya44

24 November 2022

mapped directly with Wikidata item

PubMed ID

9190035

1 reference

PubMed ID

9190035